Ofatumumab is first self-administered, targeted B-cell treatment for relapsing MS. The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (آنسة) received FDA approval


NBScience

منظمة البحوث التعاقدية

العلاج بالخلايا الجذعية